|
1
|
Webster DP, Klenerman P and Dusheiko GM:
Hepatitis C. Lancet. 385:1124–1135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Micallef JM, Kaldor JM and Dore GJ:
Spontaneous viral clearance following acute hepatitis C infection:
A systematic review of longitudinal studies. J Viral Hepat.
13:34–41. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shepard CW, Finelli L and Alter MJ: Global
epidemiology of hepatitis C virus infection. Lancet Infect Dis.
5:558–567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McHutchison JG, Lawitz EJ, Shiffman ML,
Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff
ER, et al: Peginterferon alfa-2b or alfa-2a with ribavirin for
treatment of hepatitis C infection. N Engl J Med. 361:580–593.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ghany MG, Strader DB, Thomas DL and Seeff
LB: American Association for the Study of Liver Diseases:
Diagnosis, management, and treatment of hepatitis C: An update.
Hepatology. 49:1335–1374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aghemo A and De Francesco R: New horizons
in hepatitis C antiviral therapy with direct-acting antivirals.
Hepatology. 58:428–438. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rauch A, Gaudieri S, Thio C and Bochud PY:
Host genetic determinants of spontaneous hepatitis C clearance.
Pharmacogenomics. 10:1819–1837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bowen DG and Walker CM: Adaptive immune
responses in acute and chronic hepatitis C virus infection. Nature.
436:946–952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Doyle JS, Hellard ME and Thompson AJ: The
role of viral and host genetics in natural history and treatment of
chronic HCV infection. Best Pract Res Clin Gastroenterol.
26:413–427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bull RA, Luciani F, McElroy K, Gaudieri S,
Pham ST, Chopra A, Cameron B, Maher L, Dore GJ, White PA and Lloyd
AR: Sequential bottlenecks drive viral evolution in early acute
hepatitis C virus infection. PLoS Pathog. 7:e10022432011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bochud PY, Cai T, Overbeck K, Bochud M,
Dufour JF, Müllhaupt B, Borovicka J, Heim M, Moradpour D, Cerny A,
et al: Genotype 3 is associated with accelerated fibrosis
progression in chronic hepatitis C. J Hepatol. 51:655–666. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pearlman BL and Traub N: Sustained
virologic response to antiviral therapy for chronic hepatitis C
virus infection: A cure and so much more. Clin Infect Dis.
52:889–900. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu Y and Chen S: Antiviral treatment of
hepatitis C virus infection and factors affecting efficacy. World J
Gastroenterol. 19:8963–8973. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hadziyannis SJ, Sette H Jr, Morgan TR,
Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr,
Bernstein D, Rizzetto M, et al: Peginterferon-alpha2a and ribavirin
combination therapy in chronic hepatitis C: A randomized study of
treatment duration and ribavirin dose. Ann Intern Med. 140:346–355.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Khuroo MS, Khuroo MS and Dahab ST:
Meta-analysis: A randomized trial of peginterferon plus ribavirin
for the initial treatment of chronic hepatitis C genotype 4.
Aliment Pharmacol Ther. 20:931–938. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nguyen MH, Trinh HN, Garcia R, Nguyen G,
Lam KD and Keeffe EB: Higher rate of sustained virologic response
in chronic hepatitis C genotype 6 treated with 48 weeks versus 24
weeks of peginterferon plus ribavirin. Am J Gastroenterol.
103:1131–1135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Foster GR, Hézode C, Bronowicki JP, Carosi
G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G
and Beumont M: Telaprevir alone or with peginterferon and ribavirin
reduces HCV RNA in patients with chronic genotype 2 but not
genotype 3 infections. Gastroenterology. 141:881–889, e1. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Howe J, Graham D, McMonagle P, Curry S,
Chase R, Lahser F, Ogert RA, Strizki J, Barnard RJBO, Zhang R, et
al: 844In vitro characterization of the pan-genotyope activity of
the HCV NS3/4A protease inhibitors Boceprevir and
Telapreevir. J Hepatology. 56:S3292012. View Article : Google Scholar
|
|
20
|
Jacobson IM, McHutchison JG, Dusheiko G,
Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci
P, Flisiak R, et al: Telaprevir for previously untreated chronic
hepatitis C virus infection. N Engl J Med. 364:2405–2416. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zeuzem S, Andreone P, Pol S, Lawitz E,
Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, et
al: Telaprevir for retreatment of HCV infection. N Engl J Med.
364:2417–2428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poordad F, McCone J Jr, Bacon BR, Bruno S,
Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai
N, et al: Boceprevir for untreated chronic HCV genotype 1
infection. N Engl J Med. 364:1195–1206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bacon BR, Gordon SC, Lawitz E, Marcellin
P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai
N, et al: Boceprevir for previously treated chronic HCV genotype 1
infection. N Engl J Med. 364:1207–1217. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vierling J, Flamm S, Gordon S, Lawitz E,
Bronowicki JP, Davis M, Yoshida E, Pedicone LD, Deng W, Treitel M,
et al: Efficacy of boceprevir in prior null responders to
peginterferon/ribavirin: The PROVIDE study. Hepatology.
54:796A2011.
|
|
25
|
Sulkowski M, Gardiner D, Lawitz E,
Hinestrosa F, Nelson D, Thuluvath P, Rodriguez-Torres M, Lok A,
Schwartz H, Reddy KR, et al: 1422 Potent Viral Suppression with
all-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977
(NS5B Inhibitor), +/− ribavirin, in treatment-naive patients with
chronic HCV GT1, 2, OR 3. J Hepatology. 56:S5602012. View Article : Google Scholar
|
|
26
|
Gane EJ, Stedman CA, Hyland RH, Sorensen
RD, Symonds WT, Hindes RG and Berrey MM: 1113 electron: Once daily
PSI-7977 Plus RBV in HCV GT1/2/3. J Hepatology. 56:S438–S439. 2012.
View Article : Google Scholar
|
|
27
|
Gane EJ, Stedman CA, Hyland RH, Ding X,
Svarovskaia E, Symonds WT, Hindes RG and Berrey MM: Nucleotide
polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N
Engl J Med. 368:34–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moreno C, Hezode C, Marcellin P, Bourgeois
S, Francque S, Samuel D, Zoulim F, Grange JD, Shukla U, Lenz O, et
al: Efficacy and safety of simeprevir with Peg-IFN/ribavirin in
naive or experienced patients infected with chronic HCV genotype 4.
J Hepatol. 62:1047–1055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zeuzem S, Soriano V, Asselah T, et al:
SVR4 and SVR12 with an interferon-free regimen of BI-201335 and
BI-207127, +/−ribavirin, in treatment-naıve patients with chronic
genotype-1 HCV infection: Interim results of SOUND-C2. J Hepatol
(EASL 47th Annual Meeting abstracts). 56:542012.
|
|
30
|
Lok AS, Gardiner DF, Lawitz E, Martorell
C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F,
Wind-Rotolo M, et al: Preliminary study of two antiviral agents for
hepatitis C genotype 1. N Engl J Med. 366:216–224. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jacobson IM, Brown RS Jr, Freilich B,
Afdhal N, Kwo PY, Santoro J, Becker S, Wakil AE, Pound D, Godofsky
E, et al: Peginterferon alfa-2b and weight-based or flat-dose
ribavirin in chronic hepatitis C patients: A randomized trial.
Hepatology. 46:971–981. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shiffman ML, Suter F, Bacon BR, Nelson D,
Harley H, Solá R, Shafran SD, Barange K, Lin A, Soman A and Zeuzem
S: ACCELERATE Investigators: Peginterferon alfa-2a and ribavirin
for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med.
357:124–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zeuzem S, Buti M, Ferenci P, Sperl J,
Horsmans Y, Cianciara J, Ibranyi E, Weiland O, Noviello S, Brass C
and Albrecht J: Efficacy of 24 weeks treatment with peginterferon
alfa-2b plus ribavirin in patients with chronic hepatitis C
infected with genotype 1 and low pretreatment viremia. J Hepatol.
44:97–103. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hopkins S, Bobardt M, Chatterji U,
Garcia-Rivera JA, Lim P and Gallay PA: The cyclophilin inhibitor
SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexes.
Antimicrob Agents Chemother. 56:3888–3897. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zeuzem S, Fried MW, Reddy KR, et al:
Improving the clinical relevance of pretreatment viral load as a
predictor of sustained virological response (SVR) in patients
infected with hepatitis C genotype 1 treated with peginterferon
alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (COPEGUS (R)).
Hepatology. 44:(S1). 267A–268A. 2006.
|
|
36
|
European Association for the Study of the
Liver: EASL Clinical Practice Guidelines: Management of hepatitis C
virus infection. J Hepatol. 55:245–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rocco A, Compare D, Coccoli P, Esposito C,
Di Spirito A, Barbato A, Strazzullo P and Nardone G: Vitamin B12
supplementation improves rates of sustained viral response in
patients chronically infected with hepatitis C virus. Gut.
62:766–773. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kurosaki M, Sakamoto N, Iwasaki M,
Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M
and Izumi N: Sequences in the interferon sensitivity-determining
region and core region of hepatitis C virus impact pretreatment
prediction of response to PEG-interferon plus ribavirin: Data
mining analysis. J Med Virol. 83:445–452. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yen YH, Hung CH, Hu TH, Chen CH, Wu CM,
Wang JH, Lu SN and Lee CM: Mutations in the interferon
sensitivity-determining region (nonstructural 5A amino acid
2209–2248) in patients with hepatitis C-1b infection and
correlating response to combined therapy of pegylated interferon
and ribavirin. Aliment Pharmacol Ther. 27:72–79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zeuzem S, Lee JH and Roth WK: Mutations in
the nonstructural 5A gene of European hepatitis C virus isolates
and response to interferon alfa. Hepatology. 25:740–744. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Duverlie G, Khorsi H, Castelain S, Jaillon
O, Izopet J, Lunel F, Eb F, Penin F and Wychowski C: Sequence
analysis of the NS5A protein of European hepatitis C virus 1b
isolates and relation to interferon sensitivity. J Gen Virol.
79:1373–1381. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
El-Shamy A, Nagano-Fujii M, Sasase N,
Imoto S, Kim SR and Hotta H: Sequence variation in hepatitis C
virus nonstructural protein 5A predicts clinical outcome of
pegylated interferon/ribavirin combination therapy. Hepatology.
48:38–47. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Akuta N, Suzuki F, Sezaki H, Suzuki Y,
Hosaka T, Someya T, Kobayashi M, Saitoh S, Watahiki S, Sato J, et
al: Association of amino acid substitution pattern in core protein
of hepatitis C virus genotype 1b high viral load and
non-virological response to interferon-ribavirin combination
therapy. Intervirology. 48:372–380. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Akuta N, Suzuki F, Kawamura Y, Yatsuji H,
Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, et
al: Predictive factors of early and sustained responses to
peginterferon plus ribavirin combination therapy in Japanese
patients infected with hepatitis C virus genotype 1b: Amino acid
substitutions in the core region and low-density lipoprotein
cholesterol levels. J Hepatol. 46:403–410. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Akuta N, Suzuki F, Hirakawa M, Kawamura Y,
Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M,
et al: Amino acid substitution in hepatitis C virus core region and
genetic variation near the interleukin 28B gene predict viral
response to telaprevir with peginterferon and ribavirin.
Hepatology. 52:421–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Donlin MJ, Cannon NA, Aurora R, Li J,
Wahed AS, Di Bisceglie AM and Tavis JE: Virahep-C Study Group:
Contribution of genome-wide HCV genetic differences to outcome of
interferon-based therapy in Caucasian American and African American
patients. PLoS One. 5:e90322010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Aurora R, Donlin MJ, Cannon NA and Tavis
JE: Genome-wide hepatitis C virus amino acid covariance networks
can predict response to antiviral therapy in humans. J Clin Invest.
119:225–236. 2009.PubMed/NCBI
|
|
48
|
Halfon P and Locarnini S: Hepatitis C
virus resistance to protease inhibitors. J Hepatol. 55:192–206.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
McHutchison JG, Manns MP, Muir AJ,
Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S,
Reesink HW, Garg J, et al: Telaprevir for previously treated
chronic HCV infection. N Engl J Med. 362:1292–1303. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bartels DJ, Zhou Y, Zhang EZ, Marcial M,
Byrn RA, Pfeiffer T, Tigges AM, Adiwijaya BS, Lin C, Kwong AD and
Kieffer TL: Natural prevalence of hepatitis C virus variants with
decreased sensitivity to NS3.4A protease inhibitors in
treatment-naive subjects. J Infect Dis. 198:800–807. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Kieffer TL, Sarrazin C, Miller JS, Welker
MW, Forestier N, Reesink HW, Kwong AD and Zeuzem S: Telaprevir and
pegylated interferon-alpha-2a inhibit wild-type and resistant
genotype 1 hepatitis C virus replication in patients. Hepatology.
46:631–639. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sarrazin C and Zeuzem S: Resistance to
direct antiviral agents in patients with hepatitis C virus
infection. Gastroenterology. 138:447–462. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D,
O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al: Genetic
variation in IL28B and spontaneous clearance of hepatitis C virus.
Nature. 461:798–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Rauch A, Kutalik Z, Descombes P, Cai T, Di
Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka
J, et al: Genetic variation in IL28B is associated with chronic
hepatitis C and treatment failure: A genome-wide association study.
Gastroenterology. 138:1338–1345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kenny-Walsh E: Clinical outcomes after
hepatitis C infection from contaminated anti-D immune globulin.
Irish Hepatology Research Group. N Engl J Med. 340:1228–1233. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Grebely J, Petoumenos K, Hellard M,
Matthews GV, Suppiah V, Applegate T, Yeung B, Marks P, Rawlinson W,
Lloyd AR, et al: Potential role for interleukin-28B genotype in
treatment decision-making in recent hepatitis C virus infection.
Hepatology. 52:1216–1224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tillmann HL, Thompson AJ, Patel K, Wiese
M, Tenckhoff H, Nischalke HD, Lokhnygina Y, Kullig U, Göbel U,
Capka E, et al: A polymorphism near IL28B is associated with
spontaneous clearance of acute hepatitis C virus and jaundice.
Gastroenterology. 139:1586–1592. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ramadori G and Christ B: Cytokines and the
hepatic acute-phase response. Semin Liver Dis. 19:141–155. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gao B: Cytokines, STATs and liver disease.
Cell Mol Immunol. 2:92–100. 2005.PubMed/NCBI
|
|
60
|
Fishman D, Faulds G, Jeffery R,
Mohamed-Ali V, Yudkin JS, Humphries S and Woo P: The effect of
novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6
transcription and plasma IL-6 levels, and an association with
systemic-onset juvenile chronic arthritis. J Clin Invest.
102:1369–1376. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Barrett S, Collins M, Kenny C, Ryan E,
Keane CO and Crowe J: Polymorphisms in tumour necrosis
factor-alpha, transforming growth factor-beta, interleukin-10,
interleukin-6, interferon-gamma, and outcome of hepatitis C virus
infection. J Med Virol. 71:212–218. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Minton EJ, Smillie D, Smith P, Shipley S,
McKendrick MW, Gleeson DC, Underwood JC, Cannings C and Wilson AG:
Trent Hepatitis C Study Group: Clearance of hepatitis C virus is
not associated with single nucleotide polymorphisms in the IL-1,
−6, or −10 genes. Hum Immunol. 66:127–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Oleksyk TK, Thio CL, Truelove AL, Goedert
JJ, Donfield SM, Kirk GD, Thomas DL, O'Brien SJ and Smith MW:
Single nucleotide polymorphisms and haplotypes in the IL10 region
associated with HCV clearance. Genes Immun. 6:347–357. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Paladino N, Fainboim H, Theiler G,
Schroder T, Muñoz AE, Flores AC, Galdame O and Fainboim L: Gender
susceptibility to chronic hepatitis C virus infection associated
with interleukin 10 promoter polymorphism. J Virol. 80:9144–9150.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lio D, Caruso C, Di Stefano R, Romano
Colonna G, Ferraro D, Scola L, Crivello A, Licata A, Valenza LM,
Candore G, et al: IL-10 and TNF-alpha polymorphisms and the
recovery from HCV infection. Hum Immunol. 64:674–680. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Mangia A, Santoro R, Piattelli M, Pazienza
V, Grifa G, Iacobellis A and Andriulli A: IL-10 haplotypes as
possible predictors of spontaneous clearance of HCV infection.
Cytokine. 25:103–109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kusumoto K, Uto H, Hayashi K, Takahama Y,
Nakao H, Suruki R, Stuver SO, Ido A and Tsubouchi H: Interleukin-10
or tumor necrosis factor-alpha polymorphisms and the natural course
of hepatitis C virus infection in a hyperendemic area of Japan.
Cytokine. 34:24–31. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Houldsworth A, Metzner M, Rossol S, Shaw
S, Kaminski E, Demaine AG and Cramp ME: Polymorphisms in the IL-12B
gene and outcome of HCV infection. J Interferon Cytokine Res.
25:271–276. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Mueller T, Mas-Marques A, Sarrazin C,
Wiese M, Halangk J, Witt H, Ahlenstiel G, Spengler U, Goebel U,
Wiedenmann B, et al: Influence of interleukin 12B (IL12B)
polymorphisms on spontaneous and treatment-induced recovery from
hepatitis C virus infection. J Hepatol. 41:652–658. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Yin LM, Zhu WF, Wei L, Xu XY, Sun DG, Wang
YB, Fan WM, Yu M, Tian XL, Wang QX, et al: Association of
interleukin-12 p40 gene 3′-untranslated region polymorphism and
outcome of HCV infection. World J Gastroenterol. 10:2330–2333.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
An P, Thio CL, Kirk GD, Donfield S,
Goedert JJ and Winkler CA: Regulatory polymorphisms in the
interleukin-18 promoter are associated with hepatitis C virus
clearance. J Infect Dis. 198:1159–1165. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hennig BJ, Frodsham AJ, Hellier S, Knapp
S, Yee LJ, Wright M, Zhang L, Thomas HC, Thursz M and Hill AV:
Influence of IL-10RA and IL-22 polymorphisms on outcome of
hepatitis C virus infection. Liver Int. 27:1134–1143. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Larrea E, Garcia N, Qian C, Civeira MP and
Prieto J: Tumor necrosis factor alpha gene expression and the
response to interferon in chronic hepatitis C. Hepatology.
23:210–217. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
D'Alfonso S and Richiardi PM: A
polymorphic variation in a putative regulation box of the TNFA
promoter region. Immunogenetics. 39:150–154. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wilson AG, de Vries N, Pociot F, di
Giovine FS, van der Putte LB and Duff GW: An allelic polymorphism
within the human tumor necrosis factor alpha promoter region is
strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med.
177:557–560. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wilson AG, Symons JA, McDowell TL,
McDevitt HO and Duff GW: Effects of a polymorphism in the human
tumor necrosis factor alpha promoter on transcriptional activation.
Proc Natl Acad Sci USA. 94:3195–3199. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hohler T, Kruger A, Gerken G, Schneider
PM, zum Büschenefelde Meyer KH and Rittner C: A tumor necrosis
factor-alpha (TNF-alpha) promoter polymorphism is associated with
chronic hepatitis B infection. Clin Exp Immunol. 111:579–582. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Dai CY, Chuang WL, Chang WY, Chen SC, Lee
LP, Hsieh MY, Hou NJ, Lin ZY, Huang JF, Hsieh MY, et al: Tumor
necrosis factor- alpha promoter polymorphism at position −308
predicts response to combination therapy in hepatitis C virus
infection. J Infect Dis. 193:98–101. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yee LJ, Tang J, Herrera J, Kaslow RA and
van Leeuwen DJ: Tumor necrosis factor gene polymorphisms in
patients with cirrhosis from chronic hepatitis C virus infection.
Genes Immun. 1:386–390. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Schiemann U, Glas J, Török P, Simperl C,
Martin K, König A, Schmidt F, Schaefer M and Folwaczny C: Response
to combination therapy with interferon alfa-2a and ribavirin in
chronic hepatitis C according to a TNF-alpha promoter polymorphism.
Digestion. 68:1–4. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kimura T, Saito T, Yoshimura M, Yixuan S,
Baba M, Ji G, Muramatsu M and Kawata S: Association of transforming
growth factor-beta 1 functional polymorphisms with natural
clearance of hepatitis C virus. J Infect Dis. 193:1371–1374. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Neumann-Haefelin C, Blum HE, Chisari FV
and Thimme R: T cell response in hepatitis C virus infection. J
Clin Virol. 32:75–85. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Singh R, Kaul R, Kaul A and Khan K: A
comparative review of HLA associations with hepatitis B and C viral
infections across global populations. World J Gastroenterol.
13:1770–1787. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Alric L, Fort M, Izopet J, Vinel JP,
Bureau C, Sandre K, Charlet JP, Beraud M, Abbal M and Duffaut M:
Study of host- and virus-related factors associated with
spontaneous hepatitis C virus clearance. Tissue Antigens.
56:154–158. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Thursz M, Yallop R, Goldin R, Trepo C and
Thomas HC: Influence of MHC class II genotype on outcome of
infection with hepatitis C virus. The HENCORE group. Hepatitis C
European network for cooperative research. Lancet. 354:2119–2124.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
McKiernan SM, Hagan R, Curry M, McDonald
GS, Kelly A, Nolan N, Walsh A, Hegarty J, Lawlor E and Kelleher D:
Distinct MHC class I and II alleles are associated with hepatitis C
viral clearance, originating from a single source. Hepatology.
40:108–114. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Chuang WC, Sarkodie F, Brown CJ,
Owusu-Ofori S, Brown J, Li C, Navarrete C, Klenerman P and Allain
JP: Protective effect of HLA-B57 on HCV genotype 2 infection in a
West African population. J Med Virol. 79:724–733. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Thio CL, Gao X, Goedert JJ, Vlahov D,
Nelson KE, Hilgartner MW, O'Brien SJ, Karacki P, Astemborski J,
Carrington M and Thomas DL: HLA-Cw*04 and hepatitis C virus
persistence. J Virol. 76:4792–4797. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hraber P, Kuiken C and Yusim K: Evidence
for human leukocyte antigen heterozygote advantage against
hepatitis C virus infection. Hepatology. 46:1713–1721. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Hong X, Yu RB, Sun NX, Wang B, Xu YC and
Wu GL: Human leukocyte antigen class II DQB1*0301, DRB1*1101
alleles and spontaneous clearance of hepatitis C virus infection: A
meta-analysis. World J Gastroenterol. 11:7302–7307. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Schmidt J, Thimme R and Neumann-Haefelin
C: Host genetics in immune-mediated hepatitis C virus clearance.
Biomark Med. 5:155–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Khakoo SI, Thio CL, Martin MP, Brooks CR,
Gao X, Astemborski J, Cheng J, Goedert JJ, Vlahov D, Hilgartner M,
et al: HLA and NK cell inhibitory receptor genes in resolving
hepatitis C virus infection. Science. 305:872–874. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zúñiga J, Romero V, Azocar J, Terreros D,
Vargas- MI, Torres-García D, Jiménez-Alvarez L, Vargas-Alarcón G,
Granados-Montiel J, Husain Z, et al: Protective KIR-HLA
interactions for HCV infection in intravenous drug users. Mol
Immunol. 46:2723–2727. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Lu Z, Zhang B, Chen S, Gai Z, Feng Z, Liu
X, Liu Y, Wen X, Li L, Jiao Y, et al: Association of KIR genotypes
and haplotypes with susceptibility to chronic hepatitis B virus
infection in Chinese Han population. Cell Mol Immunol. 5:457–463.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Dring MM, Morrison MH, McSharry BP, Guinan
KJ and Hagan R: Irish HCV Research Consortium, O'Farrelly C and
Gardiner CM: Innate immune genes synergize to predict increased
risk of chronic disease in hepatitis C virus infection. Proc Natl
Acad Sci USA. 108:5736–5741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Knapp S, Warshow U, Hegazy D, Brackenbury
L, Guha IN, Fowell A, Little AM, Alexander GJ, Rosenberg WM, Cramp
ME and Khakoo SI: Consistent beneficial effects of killer cell
immunoglobulin-like receptor 2DL3 and group 1 human leukocyte
antigen-C following exposure to hepatitis C virus. Hepatology.
51:1168–1175. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Romero V, Azocar J, Zúñiga J, Clavijo OP,
Terreros D, Gu X, Husain Z, Chung RT, Amos C and Yunis EJ:
Interaction of NK inhibitory receptor genes with HLA-C and MHC
class II alleles in Hepatitis C virus infection outcome. Mol
Immunol. 45:2429–2436. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Montes-Cano MA, Caro-Oleas JL,
Romero-Gómez M, Diago M, Andrade R, Carmona I, Reina Aguilar J,
Núñez-Roldán A and González-Escribano MF: HLA-C and KIR genes in
hepatitis C virus infection. Hum Immunol. 66:1106–1109. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Rauch A, Laird R, McKinnon E, Telenti A,
Furrer H, Weber R, Smillie D and Gaudieri S: Swiss HIV Cohort
Study: Influence of inhibitory killer immunoglobulin-like receptors
and their HLA-C ligands on resolving hepatitis C virus infection.
Tissue Antigens. 69:(Suppl 1). S237–S240. 2007. View Article : Google Scholar
|
|
100
|
Schott E, Witt H, Hinrichsen H, Neumann K,
Weich V, Bergk A, Halangk J, Müller T, Tinjala S, Puhl G, Neuhaus
P, et al: Gender-dependent association of CTLA4 polymorphisms with
resolution of hepatitis C virus infection. J Hepatol. 46:372–380.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zhu C, Zhang R, Liu D, Mukhtar MM, Liu W,
Peng G, Wang K, Hao Q, Xu Y, Liu F, et al: Association of
functional polymorphism of ApoB promoter with hepatitis C virus
infection. Clin Chim Acta. 401:124–127. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Sarrazin C, Berg T, Ross RS, Schirmacher
P, Wedemeyer H, Neumann U, Schmidt HH, Spengler U, Wirth S, Kessler
HH, et al: Prophylaxis, diagnosis and therapy of hepatitis C virus
(HCV) infection: The German guidelines on the management of HCV
infection. Z Gastroenterol. 48:289–351. 2010.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Ge D, Fellay J, Thompson AJ, Simon JS,
Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et
al: Genetic variation in IL28B predicts hepatitis C
treatment-induced viral clearance. Nature. 461:399–401. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Suppiah V, Moldovan M, Ahlenstiel G, Berg
T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell
E, et al: IL28B is associated with response to chronic hepatitis C
interferon-alpha and ribavirin therapy. Nat Genet. 41:1100–1104.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
105
|
Tanaka Y, Nishida N, Sugiyama M, Kurosaki
M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S,
et al: Genome-wide association of IL28B with response to pegylated
interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat
Genet. 41:1105–1109. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
106
|
Antaki N, Bibert S, Kebbewar K, Asaad F,
Baroudi O, Alideeb S, Hadad M, Abboud D, Sabah H, Bochud PY and
Negro F: IL28B polymorphisms predict response to therapy among
chronic hepatitis C patients with HCV genotype 4. J Viral Hepat.
20:59–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Rallon NI, Naggie S, Benito JM, Medrano J,
Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A,
McHutchison J and Soriano V: Association of a single nucleotide
polymorphism near the interleukin-28B gene with response to
hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.
AIDS. 24:F23–F29. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Thompson AJ, Muir AJ, Sulkowski MS, Ge D,
Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R,
et al: Interleukin-28B polymorphism improves viral kinetics and is
the strongest pretreatment predictor of sustained virologic
response in genotype 1 hepatitis C virus. Gastroenterology.
139:120–129, e18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Bochud PY, Bibert S, Negro F, Haagmans B,
Soulier A, Ferrari C, Missale G, Zeuzem S, Pawlotsky JM, Schalm S,
et al: IL28B polymorphisms predict reduction of HCV RNA from the
first day of therapy in chronic hepatitis C. J Hepatol. 55:980–988.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Scherzer TM, Hofer H, Staettermayer AF,
Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH and
Ferenci P: Early virologic response and IL28B polymorphisms in
patients with chronic hepatitis C genotype 3 treated with
peginterferon alfa-2a and ribavirin. J Hepatol. 54:866–871. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yu ML, Huang CF, Huang JF, Chang NC, Yang
JF, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, et al: Role of
interleukin-28B polymorphisms in the treatment of hepatitis C virus
genotype 2 infection in Asian patients. Hepatology. 53:7–13. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Stättermayer AF, Stauber R, Hofer H,
Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A,
Dulic-Lakovic E, et al: Impact of IL28B genotype on the early and
sustained virologic response in treatment-naïve patients with
chronic hepatitis C. Clin Gastroenterol Hepatol. 9:344–350, e2.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Jaeckel E, Cornberg M, Wedemeyer H,
Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein
C and Manns MP: German Acute Hepatitis C Therapy Group: Treatment
of acute hepatitis C with interferon alfa-2b. N Engl J Med.
345:1452–1457. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Wiegand J, Buggisch P, Boecher W, Zeuzem
S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M and
Jaeckel E: Early monotherapy with pegylated interferon alpha-2b for
acute hepatitis C infection: The HEP-NET acute-HCV-II study.
Hepatology. 43:250–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kamal SM, Fouly AE, Kamel RR, Hockenjos B,
Al Tawil A, Khalifa KE, He Q, Koziel MJ, El Naggar KM, Rasenack J
and Afdhal NH: Peginterferon alfa-2b therapy in acute hepatitis C:
Impact of onset of therapy on sustained virologic response.
Gastroenterology. 130:632–638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Holmes JA, Sievert W and Thompson AJ:
IL28B polymorphism and genetic biomarkers of viral clearance in
hepatitis C virus infection. Biomark Med. 5:461–478. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Halfon P, Bourliere M, Ouzan D, Maor Y,
Renou C, Wartelle C, Pénaranda G, Tran A, Botta D, Oules V, et al:
A single IL28B genotype SNP rs12979860 determination predicts
treatment response in patients with chronic hepatitis C Genotype 1
virus. Eur J Gastroenterol Hepatol. 23:931–935. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Ghany MG, Nelson DR, Strader DB, Thomas DL
and Seeff LB: American Association for Study of Liver Diseases: An
update on treatment of genotype 1 chronic hepatitis C virus
infection: 2011 practice guideline by the American Association for
the study of liver diseases. Hepatology. 54:1433–1444. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Ank N, Iversen MB, Bartholdy C, Staeheli
P, Hartmann R, Jensen UB, Dagnaes-Hansen F, Thomsen AR, Chen Z,
Haugen H, et al: An important role for type III interferon
(IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol.
180:2474–2485. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Li M, Liu X, Zhou Y and Su SB:
Interferon-lambdas: The modulators of antivirus, antitumor, and
immune responses. J Leukoc Biol. 86:23–32. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Honda M, Sakai A, Yamashita T, Nakamoto Y,
Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shirasaki T,
Horimoto K, et al: Hepatic ISG expression is associated with
genetic variation in interleukin 28B and the outcome of IFN therapy
for chronic hepatitis C. Gastroenterology. 139:499–509. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Urban TJ, Thompson AJ, Bradrick SS, Fellay
J, Schuppan D, Cronin KD, Hong L, McKenzie A, Patel K, Shianna KV,
et al: IL28B genotype is associated with differential expression of
intrahepatic interferon-stimulated genes in patients with chronic
hepatitis C. Hepatology. 52:1888–1896. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Jacobson IM, Catlett I, Marcellin P,
Bzowej NH, Muir AJ, Adda N, Bengtsson L, George S, Seepersaud S,
Ramachandram R, et al: 1369 Telaprevir substantially improved SVR
rates across all IL28B genotypes in the advance trial. J
Hepatology. 54:S542–S543. 2011. View Article : Google Scholar
|
|
124
|
Bronowicki JP, Hezode C, Bengtsson L, Pol
S, Bourliere M, Serfaty L, de Ledinghen V, Tran A, Benhamou Y,
Grang JD, et al: 1094 100% SVR in IL28B CC patients treated with 12
weeks of telaprevir, peginterferon and ribavirin in the PROVE2
trial. J Hepatology. 56:S430–S431. 2012. View Article : Google Scholar
|
|
125
|
Penney MS, De Souza C, Seepersaud S, Alves
K, Koziel MJ, Kauffman RS, Di Bisceglie AM and Botfield MC: 1203
All IL28B genotypes have high SVR rates in patients treated with
VX-222 in combination with Telaprevir/Peginterferon/Ribavin in the
ZENITH study. J Hepatology. 56:S476–S477. 2012. View Article : Google Scholar
|
|
126
|
Poordad F, Bronowicki JP, Gordon SC,
Zeuzem S, Jacobson IM, Sulkowski MS, Poynard TMorgan, TRBurroughs
MSniukiene V, et al: 12 IL28B polymorphism predicts virologic
response in patients with hepatitis C genotype 1 treated with
boceprevir (BOC) combination therapy. J Hepatology. 54:S62011.
View Article : Google Scholar
|
|
127
|
Sulkowski MS, Asselah T, Lalezari J,
Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J,
Datsenko Y, et al: Faldaprevir combined with pegylated interferon
alfa-2a and ribavirin in treatment-naïve patients with chronic
genotype 1 HCV: SILEN-C1 trial. Hepatology. 57:2143–2154. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Chu TW, Kulkarni R, Gane EJ, Roberts SK,
Stedman C, Angus PW, Ritchie B, Lu XY, Ipe D, Lopatin U, et al:
Effect of IL28B genotype on early viral kinetics during
interferon-free treatment of patients with chronic hepatitis C.
Gastroenterology. 142:790–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Liu S, Cipriano LE, Holodniy M, Owens DK
and Goldhaber-Fiebert JD: New protease inhibitors for the treatment
of chronic hepatitis C: A cost-effectiveness analysis. Ann Intern
Med. 156:279–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Hijikata M, Ohta Y and Mishiro S:
Identification of a single nucleotide polymorphism in the MxA gene
promoter (G/T at nt −88) correlated with the response of hepatitis
C patients to interferon. Intervirology. 43:124–127. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Knapp S, Yee LJ, Frodsham AJ, Hennig BJ,
Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC,
et al: Polymorphisms in interferon-induced genes and the outcome of
hepatitis C virus infection: Roles of MxA, OAS-1 and PKR. Genes
Immun. 4:411–419. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Suzuki F, Arase Y, Suzuki Y, Tsubota A,
Akuta N, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, et al:
Single nucleotide polymorphism of the MxA gene promoter influences
the response to interferon monotherapy in patients with hepatitis C
viral infection. J Viral Hepat. 11:271–276. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
El Bader Din NG, Salum GM, Anany MA,
Ibrahim MK, Dawood RM, Zayed N, El Abd YS, El-Shenawy R and El
Awady MK: Association of myxovirus resistance gene promoter
polymorphism with response to combined interferon treatment and
progression of liver disease in chronic HCV egyptian patients. J
Interferon Cytokine Res. 35:641–648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Persico M, Capasso M, Russo R, Persico E,
Crocè L, Tiribelli C and Iolascon A: Elevated expression and
polymorphisms of SOCS3 influence patient response to antiviral
therapy in chronic hepatitis C. Gut. 57:507–515. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Welzel TM, Morgan TR, Bonkovsky HL,
Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT,
Bashirova A, Carrington M, et al: Variants in interferon-alpha
pathway genes and response to pegylated interferon-Alpha2a plus
ribavirin for treatment of chronic hepatitis C virus infection in
the hepatitis C antiviral long-term treatment against cirrhosis
trial. Hepatology. 49:1847–1858. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Su X, Yee LJ, Im K, Rhodes SL, Tang Y,
Tong X, Howell C, Ramcharran D, Rosen HR, Taylor MW, et al:
Association of single nucleotide polymorphisms in interferon
signaling pathway genes and interferon-stimulated genes with the
response to interferon therapy for chronic hepatitis C. J Hepatol.
49:184–191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Constantini PK, Wawrzynowicz-Syczewska M,
Clare M, Boron-Kaczmarska A, McFarlane IG, Cramp ME and Donaldson
PT: Interleukin-1, interleukin-10 and tumour necrosis factor-alpha
gene polymorphisms in hepatitis C virus infection: An investigation
of the relationships with spontaneous viral clearance and response
to alpha-interferon therapy. Liver. 22:404–412. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Edwards-Smith CJ, Jonsson JR, Purdie DM,
Bansal A, Shorthouse C and Powell EE: Interleukin-10 promoter
polymorphism predicts initial response of chronic hepatitis C to
interferon alfa. Hepatology. 30:526–530. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Vidigal PG, Germer JJ and Zein NN:
Polymorphisms in the interleukin-10, tumor necrosis factor-alpha
and transforming growth factor-beta1 genes in chronic hepatitis C
patients treated with interferon and ribavirin. J Hepatol.
36:271–277. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Gracie JA, Robertson SE and McInnes IB:
Interleukin-18. J Leukoc Biol. 73:213–224. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Nakanishi K, Yoshimoto T, Tsutsui H and
Okamura H: Interleukin-18 is a unique cytokine that stimulates both
Th1 and Th2 responses depending on its cytokine milieu. Cytokine
Growth Factor Rev. 12:53–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Tsutsui H, Adachi K, Seki E and Nakanishi
K: Cytokine-induced inflammatory liver injuries. Curr Mol Med.
3:545–559. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Haas SL, Weiss C, Bugert P, Gundt J, Witt
H, Singer MV, Berg T and Böcker U: Interleukin 18 promoter variants
(−137G>C and −607C>A) in patients with chronic hepatitis C:
Association with treatment response. J Clin Immunol. 29:620–628.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Giedraitis V, He B, Huang WX and Hillert
J: Cloning and mutation analysis of the human IL-18 promoter: A
possible role of polymorphisms in expression regulation. J
Neuroimmunol. 112:146–152. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Rosen HR, McHutchison JG, Conrad AJ, Lentz
JJ, Marousek G, Rose SL, Zaman A, Taylor K and Chou S: Tumor
necrosis factor genetic polymorphisms and response to antiviral
therapy in patients with chronic hepatitis C. Am J Gastroenterol.
97:714–720. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Neuman MG, Benhamou JP, Martinot M, Boyer
N, Shear NH, Malkiewicz I, Katz GG, Suneja A, Singh S and Marcellin
P: Predictors of sustained response to alpha interferon therapy in
chronic hepatitis C. Clin Biochem. 32:537–545. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Wasmuth HE, Werth A, Mueller T, Berg T,
Dietrich CG, Geier A, Gartung C, Lorenzen J, Matern S and Lammert
F: Haplotype-tagging RANTES gene variants influence response to
antiviral therapy in chronic hepatitis C. Hepatology. 40:327–334.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Huang Y, Yang H, Borg BB, Su X, Rhodes SL,
Yang K, Tong X, Tang G, Howell CD, Rosen HR, et al: A functional
SNP of interferon-gamma gene is important for
interferon-alpha-induced and spontaneous recovery from hepatitis C
virus infection. Proc Natl Acad Sci USA. 104:985–990. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Almarri A, El Dwick N, Al Kabi S, Sleem K,
Rashed A, Ritter MA and Batchelor JR: Interferon-alpha therapy in
HCV hepatitis: HLA phenotype and cirrhosis are independent
predictors of clinical outcome. Hum Immunol. 59:239–242. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Romero-Gomez M, González-Escribano MF,
Torres B, Barroso N, Montes-Cano MA, Sánchez-Muñoz D, Núñez-Roldan
A and Aguilar-Reina J: HLA class I B44 is associated with sustained
response to interferon + ribavirin therapy in patients with chronic
hepatitis C. Am J Gastroenterol. 98:1621–1626. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Jiao J and Wang JB: Hepatitis C virus
genotypes, HLA-DRB alleles and their response to interferon-alpha
and ribavirin in patients with chronic hepatitis C. Hepatobiliary
Pancreat Dis Int. 4:80–83. 2005.PubMed/NCBI
|
|
152
|
Lindemann M, Virchow S, Ramann F,
Barsegian V, Kreuzfelder E, Siffert W, Müller N and Grosse-Wilde H:
The G protein beta3 subunit 825T allele is a genetic marker for
enhanced T cell response. FEBS Lett. 495:82–86. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Sarrazin C, Berg T, Weich V, Mueller T,
Frey UH, Zeuzem S, Gerken G, Roggendorf M and Siffert W: GNB3 C825T
polymorphism and response to interferon-alfa/ribavirin treatment in
patients with hepatitis C virus genotype 1 (HCV-1) infection. J
Hepatol. 43:388–393. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Ahlenstiel G, Nischalke HD, Bueren K, Berg
T, Vogel M, Biermer M, Grünhage F, Sauerbruch T, Rockstroh J,
Spengler U and Nattermann J: The GNB3 C825T polymorphism affects
response to HCV therapy with pegylated interferon in HCV/HIV
co-infected but not in HCV mono-infected patients. J Hepatol.
47:348–355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Schott E, Witt H, Neumann K, Bergk A,
Halangk J, Weich V, Müller T, Puhl G, Wiedenmann B and Berg T:
Association of TLR7 single nucleotide polymorphisms with chronic
HCV-infection and response to interferon-a-based therapy. J Viral
Hepat. 15:71–78. 2008.PubMed/NCBI
|
|
156
|
Lebray P, Zylberberg H, Hue S, Poulet B,
Carnot F, Martin S, Chretien Y, Pol S, Caillat-Zuckman S, Bréchot C
and Nalpas B: Influence of HFE gene polymorphism on the progression
and treatment of chronic hepatitis C. J Viral Hepat. 11:175–182.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Yee LJ, Perez KA, Tang J, van Leeuwen DJ
and Kaslow RA: Association of CTLA4 polymorphisms with sustained
response to interferon and ribavirin therapy for chronic hepatitis
C virus infection. J Infect Dis. 187:1264–1271. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Patton HM, Patel K, Behling C, Bylund D,
Blatt LM, Vallée M, Heaton S, Conrad A, Pockros PJ and McHutchison
JG: The impact of steatosis on disease progression and early and
sustained treatment response in chronic hepatitis C patients. J
Hepatol. 40:484–490. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Westin J, Lagging M, Dhillon AP, Norkrans
G, Romero AI, Pawlotsky JM, Zeuzem S, Schalm SW, Verheij-Hart E,
Negro F, et al: Impact of hepatic steatosis on viral kinetics and
treatment outcome during antiviral treatment of chronic HCV
infection. J Viral Hepat. 14:29–35. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Shah SR, Patel K, Marcellin P, Foster GR,
Manns M, Kottilil S, Healey L, Pulkstenis E, Subramanian GM,
McHutchison JG, et al: Steatosis is an independent predictor of
relapse following rapid virologic response in patients with HCV
genotype 3. Clin Gastroenterol Hepatol. 9:688–693. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Restivo L, Zampino R, Guerrera B, Ruggiero
L and Adinolfi LE: Steatosis is the predictor of relapse in HCV
genotype 3- but not 2-infected patients treated with 12 weeks of
pegylated interferon-α-2a plus ribavirin and RVR. J Viral Hepat.
19:346–352. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Conjeevaram HS, Kleiner DE, Everhart JE,
Hoofnagle JH, Zacks S, Afdhal NH and Wahed AS: Virahep-C Study
Group: Race, insulin resistance and hepatic steatosis in chronic
hepatitis C. Hepatology. 45:80–87. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Tarantino G, Conca P, Sorrentino P and
Ariello M: Metabolic factors involved in the therapeutic response
of patients with hepatitis C virus-related chronic hepatitis. J
Gastroenterol Hepatol. 21:1266–1268. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Hanouneh IA, Feldstein AE, Lopez R, Yerian
L, Pillai A, Zein CO and Zein NN: Clinical significance of
metabolic syndrome in the setting of chronic hepatitis C virus
infection. Clin Gastroenterol Hepatol. 6:584–589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Shirakawa H, Matsumoto A, Joshita S,
Komatsu M, Tanaka N, Umemura T, Ichijo T, Yoshizawa K, Kiyosawa K
and Tanaka E: Nagano Interferon Treatment Research Group:
Pretreatment prediction of virological response to peginterferon
plus ribavirin therapy in chronic hepatitis C patients using viral
and host factors. Hepatology. 48:1753–1760. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zeuzem S: Heterogeneous virologic response
rates to interferon-based therapy in patients with chronic
hepatitis C: Who responds less well? Ann Intern Med. 140:370–381.
2004.PubMed/NCBI
|
|
167
|
Fellay J, Thompson AJ, Ge D, Gumbs CE,
Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, et
al: ITPA gene variants protect against anaemia in patients treated
for chronic hepatitis C. Nature. 464:405–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Thompson AJ, Clark PJ, Singh A, Ge D,
Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, et al:
Genome-wide association study of interferon-related cytopenia in
chronic hepatitis C patients. J Hepatol. 56:313–319. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Thompson AJ, Fellay J, Patel K, Tillmann
HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, et al:
Variants in the ITPA gene protect against ribavirin-induced
hemolytic anemia and decrease the need for ribavirin dose
reduction. Gastroenterology. 139:1181–1189. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Thompson AJ, Santoro R, Piazzolla V, Clark
PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L,
et al: Inosine triphosphatase genetic variants are protective
against anemia during antiviral therapy for HCV2/3 but do not
decrease dose reductions of RBV or increase SVR. Hepatology.
53:389–395. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Hitomi Y, Cirulli ET, Fellay J,
McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ and
Goldstein DB: Inosine triphosphate protects against
ribavirin-induced adenosine triphosphate loss by adenylosuccinate
synthase function. Gastroenterology. 140:1314–1321. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Gochee PA, Powell EE, Purdie DM, Pandeya
N, Kelemen L, Shorthouse C, Jonsson JR and Kelly B: Association
between apolipoprotein E epsilon4 and neuropsychiatric symptoms
during interferon alpha treatment for chronic hepatitis C.
Psychosomatics. 45:49–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Horsburgh K, McCarron MO, White F and
Nicoll JA: The role of apolipoprotein E in Alzheimer's disease,
acute brain injury and cerebrovascular disease: Evidence of common
mechanisms and utility of animal models. Neurobiol Aging.
21:245–255. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Wada M, Marusawa H, Yamada R, Nasu A,
Osaki Y, Kudo M, Nabeshima M, Fukuda Y, Chiba T and Matsuda F:
Association of genetic polymorphisms with interferon-induced
haematologic adverse effects in chronic hepatitis C patients. J
Viral Hepat. 16:388–396. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Poynard T, Bedossa P and Opolon P: Natural
history of liver fibrosis progression in patients with chronic
hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.
Lancet. 349:825–832. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Thomas DL, Astemborski J, Rai RM, Anania
FA, Schaeffer M, Galai N, Nolt K, Nelson KE, Strathdee SA, Johnson
L, et al: The natural history of hepatitis C virus infection: Host,
viral, and environmental factors. JAMA. 284:450–456. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Davis GL, Alter MJ, El-Serag H, Poynard T
and Jennings LW: Aging of hepatitis C virus (HCV)-infected persons
in the United States: A multiple cohort model of HCV prevalence and
disease progression. Gastroenterology. 138:513–521. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Missiha SB, Ostrowski M and Heathcote EJ:
Disease progression in chronic hepatitis C: Modifiable and
nonmodifiable factors. Gastroenterology. 134:1699–1714. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Wright M, Goldin R, Fabre A, Lloyd J,
Thomas H, Trepo C, Pradat P and Thursz M: HENCORE collaboration:
Measurement and determinants of the natural history of liver
fibrosis in hepatitis C virus infection: A cross sectional and
longitudinal study. Gut. 52:574–579. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Bataller R, North KE and Brenner DA:
Genetic polymorphisms and the progression of liver fibrosis: A
critical appraisal. Hepatology. 37:493–503. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Huang H, Shiffman ML, Friedman S,
Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU,
Sninsky JJ, et al: A 7 gene signature identifies the risk of
developing cirrhosis in patients with chronic hepatitis C.
Hepatology. 46:297–306. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Marcolongo M, Young B, Dal Pero F,
Fattovich G, Peraro L, Guido M, Sebastiani G, Palù G and Alberti A:
A seven-gene signature (cirrhosis risk score) predicts liver
fibrosis progression in patients with initially mild chronic
hepatitis C. Hepatology. 50:1038–1044. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Trepo E, Potthoff A, Pradat P, Bakshi R,
Young B, Lagier R, Moreno C, Verset L, Cross R, Degré D, et al:
Role of a cirrhosis risk score for the early prediction of fibrosis
progression in hepatitis C patients with minimal liver disease. J
Hepatol. 55:38–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Thompson AJ, Clark PJ, Zhu M, Ge D,
Sulkowski MS, Muir AJ, Tillmann HL, Patel K, Naggie S, Afdhal NH,
et al: Genome wide-association study identifies IL28B polymorphism
to be associated with baseline ALT and hepatic necro-inflammatory
activity in chronic hepatitis C patients enrolled in the IDEAL
study. Journal. 52:1220A–1221A. 2010.
|
|
185
|
Stickel F, Buch S, Lau K, zu Schwabedissen
Meyer H, Berg T, Ridinger M, Rietschel M, Schafmayer C, Braun F,
Hinrichsen H, et al: Genetic variation in the PNPLA3 gene is
associated with alcoholic liver injury in caucasians. Hepatology.
53:86–95. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Trépo E, Pradat P, Potthoff A, Momozawa Y,
Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L,
Chevallier M, et al: Impact of patatin-like phospholipase-3
(rs738409 C>G) polymorphism on fibrosis progression and
steatosis in chronic hepatitis C. Hepatology. 54:60–69. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Dunn W, O'Neil M, Zhao J, Wu CH, Roberts
B, Chakraborty S, Sherman C, Weaver B, Taylor R, Olson J, et al:
Donor PNPLA3 rs738409 genotype affects fibrosis progression in
liver transplantation for hepatitis C. Hepatology. 59:453–460.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Valenti L, Aghemo A, Stättermayer AF,
Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci
P, Colombo M and Fargion S: Implications of PNPLA3 polymorphism in
chronic hepatitis C patients receiving peginterferon plus
ribavirin. Aliment Pharmacol Ther. 35:1434–1442. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Nakamura M, Kanda T, Nakamoto S, Miyamura
T, Jiang X, Wu S and Yokosuka O: No correlation between PNPLA3
rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese
patients with HCV. PLoS One. 8:e813122013. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Patin E, Kutalik Z, Guergnon J, Bibert S,
Nalpas B, Jouanguy E, Munteanu M, Bousquet L, Argiro L, Halfon P,
et al: Genome-wide association study identifies variants associated
with progression of liver fibrosis from HCV infection.
Gastroenterology. 143:1244–1252, e1-12. 2012. View Article : Google Scholar : PubMed/NCBI
|
